Proteons in the Proteometer

THE CANARY IN

THE FERMENTOR

Expedite Molecular Structure Analysis With The Proteometer™!

Novilytic Canary
Arrow Down

SOLUTIONS

Bars with Logos.jpg
CONVERT LCs INTO PROTEOFORM METERS

New "Proteometer Kit" - Coming Fall 2022

World's first technology for at-line molecular structure analysis

PHOTO%201_edited.jpg
NOVIPLEX™ PLASMA COLLECTION SOLUTIONS
(NOW TELIMMUNE)

Advanced Remote

Plasma Collection

Availible at Telimmune.com

Lifestyle 2.jpg

ENHANCED APPROACH TO PROCESS ANALYTICAL TECHNOLOGY

MASC™, Sequestron™, Luminon™

Learn about the technology & components behind Proteometer Kits

Bioreactor Banner Option 1 - pcd22Jul202

ABOUT

Novilytic is a molecular recognition company that utilizes nanotechnology to monitor the quality of lifesaving drugs.

--

A canary in a coal mine saved the lives of hundreds of miners. This same premise applied to drug fermentors can help save the billions of people and animals currently reliant on medications.

Existing methods take 4-8 hours to evaluate medication quality. Our technology performs this task nearly instantaneously.

 

These results allow pharmaceutical companies to alter or scrap their batches in a timely manner and keep them compliant with regulatory bodies. 

 

We call this patented technology "The Proteometer," which is short for Proteoform Meter. 

TESTIMONIALS

Architectural Structure

“The Proteometer is expected to play a central role in the development and commercialization of next-level biological manufacturing control strategies.

Eugene L. Inman, Ph.D.

Pharmaceutical Quality Consultant

Retired Eli Lilly and Company

Architectural Structure

“Novilytic’s Proteometer is a disruptive breakthrough that finally solves the FDA's requirement to continuously monitor t-mAb proteoforms during fermentation.”

Martin Long, BSc.
Performance Validation, Inc. – President & CEO
(Analytical Sciences Business, Brooks Life Sciences, Thermo, Perkin Elmer)

Architectural Structure

“We couldn’t be more thrilled by the results of our validation and stability analyses using the NoviPlex dry plasma cards and look forward to using them in our DMD clinical trial.”

Ines Macias-Perez, Ph.D

Principle Scientist, Product Development

Cumberland Pharmaceuticals

> 5,000

Bioreactors Globally

$8M

Raw Material Costs

0 PAT In-Line

Massive Industry Gap

The Proteometer Provides the Solution